Final Perjeta Overall Survival Data Delayed By Its Efficacy

Overall survival results from the CLEOPATRA study, which produced the progression-free survival data that supported FDA’s decision in June to give Perjeta full approval for use in combination with Herceptin and chemotherapy, were reported at the San Antonio Breast Cancer Symposium Dec. 7.